Current status of acid pump antagonists (reversible PPIs)

Yale Journal of Biology and Medicine

Volumn 69, Issue 3, 1996, Pages 233-243

  Wurst, Wilhelm ^a   Hartmann, Manfred ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; BY 067; BY 574; BY 841; IMIDAZOPYRIDINE DERIVATIVE; OMEPRAZOLE; PENTAGASTRIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVATIVE; RANITIDINE; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PH MEASUREMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE BLIND PROCEDURE; STOMACH ACID SECRETION; STOMACH PH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; GASTRIC MUCOSA; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; MALE; OMEPRAZOLE; PROTON PUMPS; PYRIDINES; TIME FACTORS;

EID: 0030428245     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Kromer, W., Postius, S., Riedel, R., Simon, W.A., Hanauer, G., Brand, U., Gönne, S., and Parsons, M.E. BY1023/SK& F96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp. Ther. 254:129-135, 1990.
2. Postius, S., Bräuer, U., and Kromer, W. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. Life Sci. 49:1047-1052, 1991.
3. Postius, S., Bräuer, U., and Kromer, W. Superior antisecretory profile of the novel acid pump antagonist BY841, compared to ranitidine. Gut 37(suppl 2):A135, 1995.
4. Sauter, R., Steinijans, V.W., Diletti, E., Böhm, A., and Schulz, H.U. Presentation of results from bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 30(suppl.):S31-S35, 1992.
5. Fuder, H., Hartmann, M., Timmer, W., Lühmann, R., Wieckhorst, G., Huber, R., Bliesath, H., Wurst, W., Postius, S., Radtke, H.W., and Lücker, P.W. First administration of the new acid pump antagonist BY841: tolerability, safety and pH-metry. Gut 37(suppl 2):A127, 1995.
6. Simon, B., Müller, P., Hartmann, M., Huber, R., Bliesath, H., Lühmann, R., Wurst, W., and Radtke, H.W. Safety, tolerability and effect on pentagastrin stimulated gastric acid output (PSAO) of the new acidpump antagonist BY841. Gut 37(suppl 2):A44, 1995.
7. Fuder, H., Hartmann, M., Timmer, W., Lühmann, R., Wieckhorst, G., Huber, R., Bliesath, H., Wurst, W., Radtke, H.W., and Lücker, P.W. Repeated oral administration of the acid pump antagonist BY841. Gut 37(suppl 2):A128, 1995.
8. 2-receptor antagonst ranitidine on intragastric pH in healthy human subjects. Gastroenterol. 108(suppl):A240, 1995.
9. Cederberg, C., Röhss, K., Lundborg, P., and Olbe, L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand. J. Gastroenterol. 28:179-184, 1993.
10. Burget, D.W., Chiverton, S.G., and Hunt, R.A. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterol. 99:345-351, 1990.
11. Howden, C.W., Burget, D.W., and Hunt, R.H. A meta-analysis to predict gastric ulcer healing from acid suppression. Gastroenterol. 100(suppl):A85, 1991.
12. Bell, N.J.V., Burget, D., Howden, C.W., Wilkinson, J., and Hunt, R.H. Appropriate acid suppression for the management of gastro-eosophageal reflux disease. Digestion 51(suppl 1):59-67, 1992.
13. Hunt, R.H. Hp and pH: Implications for the eradication of Helicobacter pylori. Scand J Gastroenterol. 28(suppl 196):12-16, 1993.